Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03055377 · ClinicalTrials.gov registry record · Phase 2

N-Acetylcysteine for Youth Cannabis Use Disorder

A Phase 2 study, sponsored by Medical University of South Carolina.

Completed
Registry status
Phase 2
Development phase
192
Enrollment target

NCT03055377 is a Phase 2 study that has completed, run by Medical University of South Carolina. The registered enrollment target is 192 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03055377, a Phase 2 study, has completed, sponsored by Medical University of South Carolina.

COMPLETED
Registry status
Phase 2
Development phase
192 participants
Enrollment target

Study Summary

This is a 12-week randomized, placebo-controlled trial of N-acetylcysteine for cannabis use disorder (CUD) in youth (N=192). Participants will be randomized to double-blind NAC or PBO, yielding two equally-allocated treatment groups. All participants will receive brief weekly cannabis cessation counseling and medication management. The primary efficacy outcome will be the proportion of negative urine cannabinoid tests during the 12-week active treatment, compared between groups.

Interventions

  • DRUG Placebo oral capsule
  • DRUG N-acetyl cysteine

Trial Details

FieldValue
Enrollment Target 192 participants
Start Date 2017-08-03
Est. Completion 2024-02-26
Phase Phase 2

What the Registry Record Tells You About NCT03055377

The ClinicalTrials.gov registry entry for NCT03055377 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 192 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo oral capsule is the first listed.

NCT03055377 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03055377 about?

NCT03055377 is a clinical study titled "N-Acetylcysteine for Youth Cannabis Use Disorder". This is a 12-week randomized, placebo-controlled trial of N-acetylcysteine for cannabis use disorder (CUD) in youth (N=192). Participants will be randomized to double-blind NAC or PBO, yielding two equally-allocated treatment groups. All participants will receive brief weekly cannabis cessation coun...

What is the current status of trial NCT03055377?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 192 participants. The study started on 2017-08-03. Estimated completion is 2024-02-26.

What interventions are being tested in trial NCT03055377?

The interventions under investigation include: Placebo oral capsule (DRUG), N-acetyl cysteine (DRUG).

Who is sponsoring clinical trial NCT03055377?

This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.